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Coenzyme Q10 is a ubiquitous component of cellular membranes and belongs to the class of benzoquinones
that mainly differ with regards to the length and composition of their hydrophobic tail. The characteristic
quinone group can accept electrons from various biological sources and is converted by a one electron
transfer to the unstable semiquinone or by a two electron transfer to the more stable hydroquinone. This
feature makes CoQ10 the bona ﬁde cellular electron transfer molecule within the mitochondrial respiratory
chain and also makes it a potent cellular antioxidant. These activities serve as justiﬁcation for its popular
use as food supplement. Another quinone with similarities to the naturally occurring CoQ10 is idebenone,
which shares its quinone moiety with CoQ10, but at the same time differs from CoQ10 by the presence of a
much shorter, less lipophilic tail. However, despite its similarity to CoQ10, idebenone cannot be isolated
from any natural sources but instead was synthesized and selected as a pharmacologically active com-
pound in the 1980s by Takeda Pharmaceuticals purely based on its pharmacological properties. Several
recent clinical trials demonstrated some therapeutic efﬁcacy of idebenone in different indications and as a
consequence, many practitioners question if the freely available CoQ10 could not be used instead. Here, we
describe the molecular and pharmacological features of both molecules that arise from their structural
differences to answer the question if idebenone is merely a CoQ10 analogue as frequently perpetuated in
the literature or a pharmaceutical drug with entirely different features.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
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Universally present in human cells, coenzyme Q10 (CoQ10) is a
ubiquitous component of all cellular membranes. However, its best
studied function lies within the mitochondrial energy producing
system as an electron transport molecule. With only some rare
exceptions CoQ10 is therefore essential to life. CoQ10 belongs to a
class of compounds that are characterized by their quinone moiety
but differ in length and composition of their hydrophobic tail
(Fig. 1). The characteristic quinone group can accept electrons from
various biological sources and is converted by a one electron
transfer to the unstable semiquinone or by a two electron transfer
to the more stable hydroquinone (Fig. 2). This feature makes CoQ10
the bona ﬁde cellular electron transfer molecule within the mi-
tochondrial respiratory chain. In addition, CoQ10 is also described
as a potent cellular antioxidant. This activity, together with lower
CoQ10 levels during ageing and some diseases serve as justiﬁcation
for its common use as food supplement. It is of interest that CoQ10
is only one among a large range of very similar molecules that are
involved in a multitude of cellular functions. Many 1,4-benzoqui-
none-containing molecules similar to CoQ10 are selectively syn-
thesized by cells from bacteria to eukaryotic cells. These molecules
harbour different tail length ranging from 0 (CoQ0) to 10 (CoQ10)
isoprenyl units. For example, the predominant form of coenzyme
Q in rats is CoQ9 compared to CoQ10 in humans (Fig. 1). While the
ubiquinone moiety present in CoQ10 is the major quinone in cells
of animal origin, plants use an entirely different quinone moiety
(plastoquinone) for photosynthesis, while still using CoQ10 within
their mitochondria.
A synthetic quinone with similarities to the naturally occurring
CoQ10 is idebenone (Fig. 1). Idebenone shares its quinone moiety
with CoQ10, but at the same time differs from CoQ10 by the pre-
sence of a much shorter, less lipophilic tail. However, despite its
similarity to CoQ10, idebenone is not synthesized by any organism
and can therefore not be isolated from any natural sources. Thus,
idebenone is a novel chemical entity, which was selected from a
medicinal chemistry programme conducted in the 1980s by Ta-
keda Pharmaceuticals as a pharmacologically active compound
purely based on its pharmacological properties. Here, we describe
the molecular and pharmacological features of idebenone that are
shared with and at the same time separate it from CoQ10 to answer
the question if idebenone is merely a CoQ10 analogue as frequently
perpetuated in the literature or a drug with entirely different
pharmacological properties.Pharmacokinetics
Despite the structural relatedness of CoQ10 and idebenone, both
molecules differ signiﬁcantly in their physicochemical properties
(Fig. 1) (Table 1). The ten isoprenyl units of the tail (50 carbon
atoms) of CoQ10 make this molecule practically insoluble in aqu-
eous solutions, which is represented by a partition coefﬁcient of
nearly 20 [1]. Idebenone on the other hand has a much shorter tailFig. 1. Chemical structure of the two quinones CoQ10 and idebenone. The ten ispopren u
and molecular weight and as a consequence bioactivation. MW: molecular weight; Log(10 carbon atoms) and unlike CoQ10, also harbours a terminal
hydroxyl group which provides the molecule with polarity. Both of
those features are responsible for a partition coefﬁcient of 3.9 for
idebenone, which leads to a much higher solubility in aqueous
solution. It is this difference in solubility that is largely responsible
for all the functional differences between two molecules that are
discussed in detail below.
It has to be stressed that CoQ10, unlike idebenone, is a phy-
siological molecule that is synthesized by all cells of the body. The
biosynthesis of CoQ10 is complex and shares some of the early
steps with the cholesterol synthesis pathway [2]. Due to the very
high lipophilicity of CoQ10 eleven specialized enzymes are pre-
sently known. These enzymes are crucial for the biosynthesis of
the lipophilic CoQ10 and hand the synthetic intermediates of CoQ10
from one enzyme to the next. As a ﬁnal step, these enzymes en-
sure that CoQ10 is effectively inserted into cellular membranes as
no soluble form of CoQ10 exists [2]. Consequently, dietary CoQ10
faces a number of hurdles with regards to transport to reach its
proposed site of action in cellular membranes. Despite its frequent
use as food supplement, there are only few reports on the phar-
macokinetics of CoQ10 in humans. Dietary CoQ10 is slowly ab-
sorbed from the intestinal tract, evidenced by a plasma Tmax of 6–
8 h [3] and it is eliminated with a half-life of about 33 h [4]. A
second plasma peak was described to occur about 24 h after oral
administration, which likely reﬂects enterohepatic recycling. There
is some suggestion that using chronic ingestion of high doses via
the diet can increase CoQ10 concentrations at least in heart and
brain tissue of rodent models [5], although it has to be noted that
CoQ9 and not CoQ10 is the predominant form found in rodents. In
rodents CoQ10 levels are kept at about 10% of those of CoQ9 under
physiological conditions and it is long known that dietary CoQ10 is
converted back to CoQ9 in rats [6]. Furthermore, there is some
evidence for metabolism of dietary CoQ10, which highlights that
the results described above cannot be easily translated to the
human situation where CoQ10 is the predominant quinone. Con-
sequently, due to the lack of data of CoQ10 metabolite production,
reliable information on tissue levels for dietary CoQ10 is not
available.
Based on the synthetic nature of idebenone, detailed in-
vestigations that took metabolic conversion into account by se-
parately measuring the intact idebenone and metabolites provided
reliable data for unmodiﬁed idebenone levels in plasma and tis-
sues. Studies in animal models have demonstrated a wide bio-
distribution of intact, unmetabolized idebenone with the highest
levels found in liver and kidney and the lowest in heart and brain
[7]. In patients, idebenone is rapidly absorbed with a tmax of 1–3 h
and also eliminated faster than CoQ10, with a half-life between 10
to 13 h [8]. Although there is uncertainty around the relevance and
accuracy of CoQ10 measurements and metabolism, the reported
pharmacokinetic differences between idebenone and CoQ10 are
likely a direct consequence of the major difference in solubility of
both molecules.nit-containing side chain of CoQ10 is responsible for major differences in solubility
D: partition coefﬁcient at physiological pH.
Fig. 2. Schematic representation of quinone bioactivation mainly by two-electron reduction (two red circles). While activation of CoQ10 preferentially occurs via the mi-
tochondrial electron transport chain (mETC), idebenone is activated to the hydroquinone by the cytoplasmic NQO1 reductase. In contrast, one electron reduction (one red
circle) to the unstable semiquinone is mostly done by the Cyp450 family in the absence of two-electron-transferring reductases and is not a favourable pathway as it
generates oxidative radicals.
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The most prominent role of CoQ10 is as an electron carrier in
the mitochondrial electron transport chain (ETC). Under physio-
logical conditions, CoQ10 accepts electrons mainly from complexes
I and II and transports them to complex III. Upon donating the
electrons to complex III, CoQ10 is able to be reduced by complexes I
and II again. This cyclic activity is essential for the mechanism of
mitochondrial energy production and hence lower CoQ10 levels
negatively impact on cellular energy levels, which is evidenced by
the severe phenotype of the reported CoQ10-deﬁciency disorders.
Biochemical evidence suggests that throughout this cyclic electron
transport process CoQ10, due to its highly lipophilic nature, is
ﬁrmly anchored to and embedded within in the inner mitochon-
drial membrane.
Given the structural similarity to CoQ10 at the level of the
quinone moiety (Fig. 1), it was always assumed that idebenone
also has similar properties with regards to cellular electron
transport. Contrary to this notion however, there is evidence that
in the presence of physiological levels of mitochondrial CoQ10,
idebenone directly modulates mitochondrial respiration and en-
ergy production, which suggest that idebenone has characteristics
that are distinct from those of CoQ10. It has to be noted that the
majority of reports that observed effects of idebenone on re-
spiratory activity used isolated mitochondria. Since we now know
that idebenone also facilitates important redox-functions outside
the mitochondria [9], these studies using isolated mitochondria
not only misrepresent the activity of idebenone but are also re-
sponsible for many conﬂicting reports, Therefore only the most
relevant studies will be mentioned brieﬂy below.
Roles in the electron transport chain
Sugiyama et al. [10] were the ﬁrst to observe in isolated rat
brain mitochondria that idebenone decreased state 3 respiration in
a concentration-dependent manner when using a complex I sub-
strate. However, when using a complex II substrate, the authors
described that the respiratory and phosphorylating activities of
isolated mitochondria were left unchanged. Sugiyama et al. [10]
also demonstrated that in line with CoQ10, reduced idebenone is
rapidly converted back to the oxidized quinone form through
oxidation by complex III of the respiratory chain. Although ide-
benone markedly inhibited complex I III (NADH-cytochrome creductase) activity in this system, the authors also reported a
surprising stimulation of complex I activity by idebenone. How-
ever, given the low basal NADH-ubiquinone reductase activity
observed, rather than measuring mitochondrial complex I activity,
it is more likely that other quinone oxidoreductases such as NQO1
were detected, which co-puriﬁed with the mitochondrial pre-
paration [9]. Overall, despite the use of different experimental
systems by different investigators, there is consensus that idebe-
none is an efﬁcient substrate for the complexes II and III and in
contrast to CoQ10, a relatively slow substrate for complex I [10–12].
Idebenone as complex I inhibitor
In fact, more than just being an inefﬁcient substrate, multiple
studies consistently detected inhibition of complex I by idebenone,
in contrast to the function of CoQ10 [10–17,19,20]. Recent data
conﬁrm this inhibitory activity of idebenone using the sophisti-
cated electrochemical detection of proton translocating activity of
isolated mitochondrial membranes [16]. This inhibition of complex
I by idebenone is thought to be based on the slow release of re-
duced idebenone from the CoQ10 binding site within complex I,
which therefore interferes with the physiological reduction of
CoQ10 [15]. One possible explanation for this inhibitory activity is
based on the size of the quinone binding pocket of complex I. The
long lipophilic tail of CoQ10 safely secures the molecule in the
mitochondrial membrane, while still allowing the quinone moiety
to enter into the quinone binding pocket of complex I. Idebenone
on the other hand can be expected by its much shorter tail to
completely enter the binding pocket, which likely results in a
much longer time within the pocket [15]. This difference in tail
size and the arising difference in its interaction with complex I
make idebenone, quite contrary to CoQ10, a competitive inhibitor
of complex I.
Activation of alternative pathways by idebenone
Given the importance of complex I for energy production, it
appears counterintuitive that inhibition of complex I by idebenone
could be associated with any beneﬁcial therapeutic effects, unless
idebenone could compensate this inhibition by utilizing other
metabolic pathways to generate energy. In fact, there is evidence
from several studies that idebenone can activate different complex
I-independent metabolic pathways. One of those idebenone-
Fig. 3. Schematic representation of the different electron transport pathways favoured by the two quinones CoQ10 and idebenone. Black arrow: favoured pathway; grey
arrow: minor pathway.
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mechanism that could support mitochondrial energy production
in the presence of dysfunctional complex I [11]. Indeed, this ac-
tivity was substantiated and later extended by several reports il-
lustrating that idebenone utilizes and activates further complex
I-independent metabolic pathways in the presence of
CoQ10 [1,9,17,18] (Fig. 3). One of those is the glycerophosphate
(G3PDH) shuttle. This mechanism supplies extra energy from a
non-mitochondrial source into the mitochondria and is pre-
dominantly active in tissues with high energy demand. First de-
scribed by James et al. [12] and studied in more detail by Rauchova
et al. [17,19,20], idebenone efﬁciently activates this metabolic
pathway in vitro and in vivo in the presence of physiological levels
of CoQ10 by a so far unknown mechanism.
An additional idebenone-dependent metabolic pathway that
transfers energy equivalents from the cytosol directly into the
mitochondrial respiratory chain, was reported recently [1,9,18].
Here, upon entering the cell, idebenone is efﬁciently reduced by
the cytoplasmic enzyme NADH-quinone oxidoreductase 1 (NQO1)
as part of the cellular response to detoxify quinones and to prevent
production of ROS. The resulting active form of idebenone subse-
quently enters the mitochondria to become re-oxidized by com-
plex III of the mitochondrial electron transport chain. In line with
this “catalytic” model of repeatedly donating electrons derived
from the cytoplasma directly to complex III, idebenone is able to
directly circumvent complex I III‐dependent electron trans-
port [9,18] (Fig. 3). Indeed, under conditions of acute rotenone
treatment, which efﬁciently inactivates complex I function and
abolishes cellular energy levels, this NQO1-dependent activation
of idebenone is able to increase mitochondrial membrane poten-
tial and restore cellular ATP levels in the presence of physiological
levels of CoQ10 (Table 1) [1,9,18].Table 1
Summary of structural and mechanistic differences between CoQ10 and idebenone.
Parameter CoQ10
Chemical formula C59H90O4
Molecular weight (g/mol) 863.49
Solubility; log D (pH 7.4) 19.12
Ability to cross membranes No
In vivo t max 6–8 h
In vivo t 1/2 About 33 h
Complex I inhibitor No
Complex II substrate Yes
Complex III substrate Yes
Reduction by NQO1 very low
Activation of G3PDH shuttle Not reported
Rescue of ATP levels in the absence of functional
complex I (the higher the better)
0%
Reduction of lipid peroxide levels (the lower the
better)
9375%
Effect on mitochondrial. membrane potential
(ΔΨm)
106%
Proposed mode(s) of action Membrane-localized antioxid
port activity in mitochondrialOverall, in the presence of CoQ10, idebenone treatment leads to
a shift away from complex I-dependent respiration towards al-
ternative pathways that either use complex II dependent sub-
strates or utilize cytoplasmic electron equivalents, which are fed
directly into complex III. The combined results of this idebenone-
modiﬁed metabolism lead to a largely complex I-independent
form of respiration. It is again important to state that the ability of
idebenone to activate these alternative pathways is absolutely
dependent on a balanced solubility that allows it to shuttle be-
tween cytosol and mitochondrial membranes [1]. Consequently, at
present there is no evidence to suggest that dietary CoQ10 can
activate the alternative modes of energy production described for
idebenone above. Given that complex I dysfunction is the major
cause of mitochondrial dysfunction in a multitude of disorders
ranging from classic mitochondrial diseases to neuromuscular
disorders such as Duchene Muscular Dystrophy (DMD) and neu-
rological disorders such as glaucoma [21], this functional differ-
ence between CoQ10 and idebenone rationalizes the use of
idebenone.Antioxidative activities of idebenone and CoQ10
The naturally occurring CoQ10 is described by numerous re-
ports as a potent physiological antioxidant (reviewed by Littarru
and Tiano [22]). Within the cell, CoQ10 can detoxify radicals and is
important to protect cellular membranes against lipid peroxida-
tion. This information is based on the study of human CoQ10 de-
ﬁciency disorders that are associated with low levels of CoQ10,
high levels of ROS and most importantly, which can be treated
with exogenous CoQ10 supplementation. Consequently, CoQ10 is
widely used in indications that are thought to be associated withIdebenone
C19H30O5
338.44
3.91
Yes
1–3 h
10–15 h
Yes
Yes
Yes
Yes
Yes
up to 80%
4577%
116%
ant, electron trans-
respiratory chain
Antioxidant in multiple cellular compartments; redox
function and energy rescue via alternative pathways
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as oral supplement or therapeutic compound is still disputed [23].
Since idebenone shares the identical quinone group with CoQ10, it
is not surprising that it is also reported to be a potent anti-oxidant.
The effects of idebenone on oxidative stress and lipid peroxidation
were investigated by numerous studies that consistently reported
a high degree of protection against oxidative stress in vitro and
in vivo [17,24–35]. Concentrations needed to achieve protection
against ROS-induced toxicity by idebenone varied extensively
depending on the cellular model used. Idebenone concentrations
as low as 10 nM efﬁciently inhibited mitochondrial ROS formation
[17], while using an ex-vivo retina model 1 mM idebenone fully
protected against acute oxidative stress and cell death [28].
Importantly, lipid peroxidation-induced changes to mitochon-
drial membrane integrity are thought to directly inhibit mi-
tochondrial respiratory function. Several studies demonstrated an
inverse relationship between the extent of experimentally-in-
duced lipid peroxidation and mitochondrial respiration, which
could be normalized by idebenone treatment [10,36]. Although,
lipid peroxidation impaired the activity of complexes II, III and V,
in this study idebenone treatment speciﬁcally protected complex
III function, which is likely based on the interaction of reduced
idebenone with complex III [36]. The authors therefore suggested
that lipid peroxidation is a major contributing factor leading to
impairment of complex III function and therefore, lipophilic anti-
oxidants like idebenone are more likely to prevent this particular
type of macromolecular damage.
This protective activity of idebenone in preventing ROS-in-
duced mitochondrial dysfunction was also tested in human tissue
[37]. However, in contrast to the results by Cardoso et al. [36],
idebenone also protected complex II activity against ROS-induced
injury in this system [37]. The authors noted that this protective
effect was dependent on the conversion of idebenone into the
reduced quinol form by the respiratory chain.
It is important to point out that evidence for the antioxidant
activity of both idebenone and CoQ10 are largely derived from in
vitro and ex vivo studies. The few studies that looked at anti-
oxidant function in vivo did so by demonstrating reduced bio-
markers of oxidative stress in intact organisms in response to
treatment with both molecules. This obviously harbours the pos-
sibility that both molecules could prevent oxidative stress by in-
direct mechanisms such as the upregulation of endogenous anti-
oxidative defence mechanisms. However, at least one paper has
reported a direct anti-oxidative activity of idebenone in vivo using
electron spin resonance in the presence of CoQ10 [26], which
suggests that at least idebenone can act as a bona ﬁde antioxidant
in vivo.
Overall, most biochemical studies agree that both CoQ10 and
idebenone can inhibit the generation of reactive oxygen species
(ROS), however, given the differences in solubility and therefore
cellular localization of both molecules, no information is available
if their antioxidative activities are restricted to only certain cellular
compartments. In this context, it is important to point out that
nearly all described antioxidant effects of idebenone have been
demonstrated in systems that display physiological levels of CoQ10.
Positive effects of CoQ10 administration in cells with physiological
levels of CoQ10 could suggest that the amount or localization of
quinone, CoQ10 or idebenone, are the rate limiting factors for de-
toxiﬁcation of ROS and that the quinone-dependent antioxidative
activity is not saturated under physiological conditions. However,
it could also suggest that idebenone is able to detoxify ROS in a
manner distinct from that of CoQ10 or that the conditions for
bioactivation of both molecules differ signiﬁcantly based on their
signiﬁcant physicochemical differences described above.Differences in bioactivation
It is important to point out that both idebenone and CoQ10 are
only active as antioxidants or electron donors in the fully reduced
hydroquinone form [32]. Therefore, both molecules can be re-
garded as pro-drugs that require bioactivation to become anti-
oxidants. For their function as electron donors, the same require-
ment applies since only the activated hydroquinones can donate
electrons into the electron transfer chain. Consequently, next to
tissue distribution and cellular concentrations of both molecules,
bioactivation appears to be a rate limiting step for their speciﬁc
activities. In this context the extreme difference in the solubility of
both molecules has to be remembered. As a consequence of its
very high lipophilicity, CoQ10 is only present within cellular
membranes [38], while idebenone with its much lower lipophili-
city is found equally distributed in mitochondria and cytoplasm as
shown for example in brain tissue [7,39]. This difference in loca-
lization determines the access of both molecules to different re-
ductases that localize to different cellular compartments. After
entering the cell, idebenone, with its much higher solubility
compared to CoQ10 is rapidly and exclusively activated by NQO1
[9]. On the other hand reduction of CoQ10 within mitochondrial
membranes is dependent on the activity of the respiratory com-
plexes I and II. Despite a report that CoQ10 can also be activated by
NQO1, this activity, if at all speciﬁc, is at least 1000-fold lower
compared to the reduction of idebenone by NQO1 [9,40] and it is
likely that extra-mitochondrial CoQ10 is reduced by another re-
ductase altogether [41]. Therefore, in the context of mitochondrial
disorders, it appears likely that efﬁcient reduction of CoQ10 cannot
be achieved since this bioactivation is largely dependent on intact
mitochondrial activity. On the other hand, based on its mode of
bioactivation by cytoplasmic NQO1, idebenone can still be efﬁ-
ciently reduced under conditions of mitochondrial dysfunction
since NQO1 utilizes mitochondria-independent electron equiva-
lents that are generated for example by glycolysis in the
cytoplasm.Can idebenone substitute for CoQ10?
As pointed out before, most studies on the activities of idebe-
none have been carried out in cells and tissues that contained
physiological levels of CoQ10. Although, reduced CoQ10 levels have
been described for the process of ageing, for most mitochondrial
disorders and also in nearly all experimental systems where ide-
benone was tested, there is no evidence to suggest that CoQ10
levels are altered. Measurable results of idebenone-treatment
therefore indicate that either idebenone has different protective
activities compared to those of CoQ10 or that under physiological
conditions only suboptimal levels of CoQ10 are available. The latter
option would imply that idebenone simply acts by substituting for
CoQ10. This possibility was tested and López et al. [42] clearly
showed that in cells deﬁcient in CoQ10 biosynthesis, idebenone
was unable to substitute for CoQ10 in terms of normalizing elec-
tron ﬂow or restoring ATP levels, which are the main functions of
cellular CoQ10. Similar results were obtained in CoQ10 deﬁcient
mouse cells (genetic Coq7 mutants) where idebenone was also
unable to rescue viability [43]. These pre-clinical results are
strongly supported by a report of idebenone supplementation in a
patient with CoQ10 deﬁciency [44]. After switching a young patient
with a CoQ10 deﬁciency syndrome from CoQ10 supplementation to
idebenone, his clinical and metabolic symptoms worsened mark-
edly. Only after returning the patient to CoQ10 supplementation
did his condition return to the state before idebenone treatment
had commenced [44]. In another case, a patient with Leigh disease
was treated with CoQ10, which coincided with a worsening of his
N. Gueven et al. / Redox Biology 4 (2015) 289–295294condition that only normalized after commencing treatment with
idebenone instead [45]. These results highlight that idebenone
cannot be used as a CoQ10 replacement and that the protective
activities of idebenone are unrelated to the activities shared with
CoQ10. Based on these functional differences CoQ10 can therefore
also not substitute for idebenone.Conclusions
Based on their partial structural relatedness, CoQ10 and idebe-
none share the ability to act as potent antioxidants and to donate
electrons to complex III of the ETC. Beyond this however, both
molecules differ signiﬁcantly with regards to pharmacokinetics,
bioactivation and modulation of cellular energy production mainly
due to their different tail structure resulting in different solubility
in aqueous solutions. This feature leads to different subcellular
localization of both molecules, which in turn affects their inter-
actions with different proteins, enzymes and pathways. As a
consequence, bioactivation of mitochondrial CoQ10 is strictly de-
pendent on mitochondrial function, while idebenone is bioacti-
vated predominantly in the cytoplasm and is not dependent on
mitochondrial function. As another consequence of different mo-
lecular structure, CoQ10 largely drives complex I dependent re-
spiration in contrast to idebenone, which favours alternative,
complex I-independent pathways. Therefore, based on the current
scientiﬁc information, including the studies and results described
above, the synthetic idebenone harbours an entirely different re-
pertoire of molecular activities compared to the natural CoQ10. As
a consequence, idebenone and CoQ10 are unable to substitute for
each other. Thus, the currently used habit of many authors of
scientiﬁc publications and internet sites of referring to idebenone
as a CoQ10 analogue lacks any scientiﬁc evidence.Conﬂict of interest
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